Granata Bio, a Boston, MA-based biotechnology firm targeted on advancing fertility therapeutics, acquired an funding from Gedeon Richter.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to increase operations and its R&D efforts.
Led by CEO Evan Sussman, Granata Bio is a biopharmaceutical firm which focuses on girls’s well being and infertility. Its pipeline features a vary of fertility therapies, with collaborations spanning a number of drug lessons to handle unmet wants in reproductive medication.
The corporate is the mum or dad firm of Oviva Therapeutics, Inc., a completely owned subsidiary creating therapeutics geared toward preserving ovarian perform and increasing feminine well being span.
FinSMEs
15/05/2025
